The schedule of formal patient-focused drug development meetings will end along with PDUFA V later this month, but the US FDA is planning more patient engagement efforts – and the big public meetings might not disappear entirely.
FDA conducted the last of its planned meetings seeking opinions from patients on various diseases Sept. 25 with a session on hereditary angioedema
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?